<code id='ADEF5217B9'></code><style id='ADEF5217B9'></style>
    • <acronym id='ADEF5217B9'></acronym>
      <center id='ADEF5217B9'><center id='ADEF5217B9'><tfoot id='ADEF5217B9'></tfoot></center><abbr id='ADEF5217B9'><dir id='ADEF5217B9'><tfoot id='ADEF5217B9'></tfoot><noframes id='ADEF5217B9'>

    • <optgroup id='ADEF5217B9'><strike id='ADEF5217B9'><sup id='ADEF5217B9'></sup></strike><code id='ADEF5217B9'></code></optgroup>
        1. <b id='ADEF5217B9'><label id='ADEF5217B9'><select id='ADEF5217B9'><dt id='ADEF5217B9'><span id='ADEF5217B9'></span></dt></select></label></b><u id='ADEF5217B9'></u>
          <i id='ADEF5217B9'><strike id='ADEF5217B9'><tt id='ADEF5217B9'><pre id='ADEF5217B9'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:7
          NIH headquarters
          NIH research fellows want to unionize, in large part because they want a raise. Will that mean less money for grants? Lydia Polimeni/NIH

          Several thousand research fellows at the National Institutes of Health want to unionize, in large part because they want to raise their pay stipends to something resembling a living wage near the agency headquarters in Bethesda, Md. But with a Congress that is looking on in suspicion at the NIH’s research and a debt ceiling deal that limits budget increases, where is the money going to come from?

          Unlike private companies, federal agencies can’t always just give raises. This varies widely across the government, and from position to position. NIH trainees actually have it better than most, because they aren’t subject to the rigid federal pay scale that governs how much most people working in the administration can make. That doesn’t mean, however, that there’s always money for raises. It’s Congress, not the NIH itself, that sets the agency’s budget.

          advertisement

          Finding money for raises, therefore, necessarily means taking money from somewhere else, said Richard Freeman, a professor of economics at Harvard.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Shionogi licenses Pompe disease therapy from Maze Therapeutics
          Shionogi licenses Pompe disease therapy from Maze Therapeutics

          MazeTherapeuticsCEOJasonColomaCourtesyAfterseeingitslastdealgobustinthefaceofregulatoryscrutiny,Maze

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          There’s no way to know how good AI health technologies are

          AdobeArtificialintelligencehastheabilitytorevolutionizehumanhealth.Itisusedtodetect potentiallycance